All > Blood Pressure > Knoxville

VI-0521 for High Blood Pressure

Phase-Based Progress Estimates
3
Effectiveness
3
Safety
High Blood PressureVI-0521 - Drug
Eligibility
18 - 75
All Sexes
What conditions do you have?
Select

Study Summary

This trial is testing whether Qsymia can help lower blood pressure, compared to a placebo and another drug called phentermine.

Eligible Conditions
  • High Blood Pressure

Treatment Effectiveness

Effectiveness Progress

3 of 3
This is further along than 93% of similar trials

Similar Trials

1
Dietary Intervention
1
Phentermine/Topiramate (Qsymia)
1
Dose 3

Study Objectives

1 Primary · 2 Secondary · Reporting Duration: Baseline to Week 8

Baseline to Week 8
Change from baseline to Week 8 in mean diastolic blood pressure as measured by 24-hr ABPM
Change from baseline to Week 8 in mean systolic blood pressure as measured by 24-hr ABPM
Mean change in systolic and diastolic blood pressure from baseline to Week 8 as measured in clinic

Trial Safety

Safety Progress

3 of 3
This is further along than 85% of similar trials

Similar Trials

1
Dietary Intervention
1
Phentermine/Topiramate (Qsymia)
2
Dose 3

Side Effects for

VI-0521 Mid
15%constipation
14%paresthesia
13%dry mouth
12%Upper Respiratory Tract Infection
11%Nasopharyngitis
7%dysgeusia
7%dizziness
7%headache
7%sinusitis
6%insomnia
6%back pain
6%diarrhea
5%arthralgia
5%urinary tract infection
4%bronchitis
4%nausea
4%fatigue
This histogram enumerates side effects from a completed 2009 Phase 3 trial (NCT00553787) in the VI-0521 Mid ARM group. Side effects include: constipation with 15%, paresthesia with 14%, dry mouth with 13%, Upper Respiratory Tract Infection with 12%, Nasopharyngitis with 11%.

Trial Design

3 Treatment Groups

Phentermine 30mg
1 of 3
VI-0521 Top Dose (Phentermine 15 mg + Topiramate 92 mg)
1 of 3
Placebo
1 of 3

Active Control

Experimental Treatment

Non-Treatment Group

555 Total Participants · 3 Treatment Groups

Primary Treatment: VI-0521 · Has Placebo Group · Phase 4

VI-0521 Top Dose (Phentermine 15 mg + Topiramate 92 mg)
Drug
Experimental Group · 1 Intervention: VI-0521 · Intervention Types: Drug
Phentermine 30mg
Drug
ActiveComparator Group · 1 Intervention: Phentermine · Intervention Types: Drug
Placebo
Drug
PlaceboComparator Group · 1 Intervention: Placebo · Intervention Types: Drug
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
VI-0521
2008
Completed Phase 3
~5640

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: baseline to week 8

Who is running the clinical trial?

VIVUS LLCLead Sponsor
43 Previous Clinical Trials
10,039 Total Patients Enrolled

Eligibility Criteria

Age 18 - 75 · All Participants · 3 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You are willing and able to wear ABPM monitor apparatus for 24 hours at beginning and end of study.

Who else is applying?

What state do they live in?
California50.0%
Florida50.0%
How old are they?
65+100.0%
What site did they apply to?
Clinical Site100.0%
What portion of applicants met pre-screening criteria?
Met criteria100.0%
References

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top